Accordingly, in the RCC cohort, patients with a VHL mutation demonstrated a significant survival benefit compared to non-VHL-mutated patients (Fig. 8I), exceeding the predictive value of tumor mutational burden (Fig. S6). This evidence concerns the gene VHL and renal cell carcinoma.